Evidence map›Paper›PMID 33347707›Full record

ArticleCancer medicine2021

AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.

Michael Ozga, Qiuhong Zhao, Don Benson, Patrick Elder, Nita Williams, Naresh Bumma, Ashley Rosko, Maria Chaudhry, Abdullah Khan, Srinivas Devarakonda and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. The molecular landscape of AL amyloidosis.British journal of haematology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.Journal of the National Comprehensive Cancer Network : JNCCN · 2023
    Review
  9. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.Methodist DeBakey cardiovascular journal · 2022
    Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 1 institution in 1 country.

Michael OzgaDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Qiuhong ZhaoDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Don BensonDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Patrick ElderDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Nita WilliamsDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Naresh BummaDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Ashley RoskoDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.ORCID 0000-0001-5875-3214
Maria ChaudhryDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Abdullah KhanDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.ORCID 0000-0003-2166-2583
Srinivas DevarakondaDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Rami KahwashDivision of Cardiology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Ajay VallakatiDivision of Cardiology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Courtney CampbellDivision of Cardiology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Samir V ParikhDivision of Nephrology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Salem AlmaaniDivision of Nephrology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Jason ProsekDivision of Nephrology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Jordan BittengleDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Katherine PfundDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Samantha LoRussoDepartment of Neurology, The Ohio State University, Columbus, OH, USA.
Miriam FreimerDepartment of Neurology, The Ohio State University, Columbus, OH, USA.
Elyse RedderDepartment of Oncology Rehabilitation, The Ohio State University, Columbus, OH, USA.
Yvonne EfeberaDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.
Nidhi SharmaDivision of Hematology, Department. of Internal Medicine, The Ohio State University Comprehensive Cancer Center Columbus, OH, USA.ORCID 0000-0002-1302-7099
The Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic light chain (AL) amyloidosis is a clonal plasma-cell neoplasm that carries a poor prognosis. Although AL amyloidosis and Multiple Myeloma (MM) can co-exist and share various cytogenetic chromosomal abnormalities, little is known about Fluorescent in situ hybridization (FISH) and its prognostic relevance in AL amyloidosis.

aimThe study aims to evaluate the most prevalent FISH cytogenetic abnormalities in AL patients as independent prognostic factors, and assess the impact of cytogenetics on the survival of high-risk cardiac AL patients. MATERIALS &

methodsThis retrospective study reviewed 113 consecutive AL patients treated at The Ohio State University (OSU). Patients were divided into subgroups based on FISH data obtained within 90 days of diagnosis. Hyperdiploidy was defined as trisomies of at least 2 chromosomal loci. Primary endpoints were progression free survival (PFS) and overall survival (OS). Kaplan Meier curves were used to calculate PFS and OS. The log-rank test and Cox proportional hazard models were used to test the equality of survival functions and further evaluate the differences between groups.

resultsFISH abnormalities were detected in 76% of patients. Patients with abnormal FISH trended toward lower overall survival (OS) (p=0.06) and progression free survival (PFS) (p=0.06). The two most prevalent aberrations were translocation t(11;14) (39%) and hyperdiploidy-overall (38%). Hyperdiploidy-overall was associated with worsening PFS (p=0.018) and OS (p=0.03), confirmed in multivariable analysis. Patients with del 13q most frequently had cardiac involvement (p=0.006) and was associated with increased bone marrow plasmacytosis (p=0.02). Cardiac AL patients with no FISH abnormalities had much improved OS (p=0.012) and PFS (p=0.018)

conclusionsOur findings ultimately reveal the association of hyperdiploidy on survival in AL amyloidosis patients, including the high-risk cardiac AL population.

Indexed as

AneuploidyChromosome AberrationsTranslocation, GeneticAdultAgedAged, 80 and overCombined Modality TherapyFemaleFollow-Up StudiesHumansImmunoglobulin Light-chain AmyloidosisIn Situ Hybridization, FluorescenceMaleMiddle AgedPrognosisRetrospective Studiesamyloidosisfluorescent in situ hybridizationlight-chain amyloidosismyelomaplasma cell burdensurvival

Identifiers

PMID33347707
PMCPMC7897960
OpenAlexW3115901167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.